Physician profile
Kai Quin
NPI 1639435761
$3,023.45
in general payments reported to CMS, 2019-2025
15 companies · $36.60 in 2025
The $36.60 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,292 · 2020: $604 · 2022: $14.72 · 2023: $57.42 · 2024: $19.25 · 2025: $36.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $76.67 · Education: $36.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $76.67 |
| Education | $36.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $848.30 | 2019-2020 | |
| Abbvie INC. | $379.42 | 2019-2020 | |
| Genentech USA, INC. | $323.23 | 2019-2022 | |
| Pfizer INC. | $278.28 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $265.76 | 2019-2020 | |
| Ucb, INC. | $222.04 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $203.04 | 2019-2020 | |
| Janssen Biotech, INC. | $179.23 | 2019-2020 | |
| Glaxosmithkline, LLC. | $114.27 | 2019-2020 | |
| Celgene Corporation | $77.35 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $42.87 | 2019-2020 | |
| Pacira Therapeutics, INC. | $33.58 | 2019 | |
| Medexus Pharma, INC. | $27.67 | 2019 | |
| Lilly USA, LLC | $15.84 | 2019 | |
| Merck Sharp & Dohme LLC | $12.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kai Quin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.